Zealand Pharma to delist in US

The Danish biotech company informs US investors that trading of its American depositary shares will cease in November.


Zealand Pharma is returning exclusively to the stock exchange in Denmark, and on Monday, the Danish biotech company informed holders of its American depositary shares (ADS) that it intends to delist from the New York-based Nasdaq Global Select Market in the US, according to a press release.

An ADS is evidenced by an American depository receipt, or ADR, which is issued by a bank and offers a way for US investors to invest in overseas companies on line with domestic trading.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs